# Effects of CSL324 in the Lung After Segmental Challenge

> **NCT05653713** · PHASE1 · COMPLETED · sponsor: **CSL Behring** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** CSL324
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05653713
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-20
- **Primary completion:** 2023-07-21
- **Final completion:** 2023-07-21
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653713, "Effects of CSL324 in the Lung After Segmental Challenge". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05653713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*